9th Advances Against Aspergillosis and Mucormycosis

Palazzo dei Congressi Lugano, Lugano, Switzerland

27 – 29 February 2020

9th Advances Against Aspergillosis and Mucormycosis

Palazzo dei Congressi Lugano, Lugano, Switzerland

27 – 29 February 2020

9th Advances Against Aspergillosis and Mucormycosis

Palazzo dei Congressi Lugano, Lugano, Switzerland

27 – 29 February 2020

Programme

Go directly to a day’s programme
Thursday | Friday | Saturday

Thursday 27 February 2020 – Day 1

Meet the Professor

08:00 – 08:55ECMM and ISHAM joint session: Excellence centres, fellows, guidelines, educational initiatives, working groups and publishing
Martin Hönigl, MD & Arunaloke Chakrabarti, MD
08:00 – 08:55Kids, difficult asthma and fungus
Andrew Bush, MD
 
09:00 – 09:15Introduction and summary of new antifungal drugs
David W. Denning, MBBS
                               

Aspergillus: Modelling the Host and Beyond

Moderators: David B. Corry, MD, Richard B. Moss, MD & David S. Perlin, PhD
09:20 – 09:45IL-22 and tryptophan metabolism in antifungal host defense
Teresa Zelante, PhD
09:45 – 10:00Abstract #49: Uncoupling of cytokine signaling and LC3 associated phagocytosis (LAP) drives the development of invasive aspergillosis in patients with sepsis
Tonia Akoumianaki, PhD
10:00 – 10:25Respiratory epithelial interaction
Kirk M. Druey, MD
10:25 – 10:40Abstract #45: “Invasive aspergillosis on-a-chip” – a novel disease model to study Aspergillus fumigatus infection in the human lung
Susann Hartung, PhD
10:40 – 11:05IL-17 immunity: from Aspergillus to Candida
Petra Bacher, PhD
11:05 – 11:35
Coffee Break

Management of the Next Decade

Moderators: Arunaloke Chakrabarti, MD, Thomas F. Patterson, MD & Bart-Jan Kullberg, MD PhD
11:35 – 12:00Genomic predisposition and adaptation ito virulence in aspergillosis
Paul Bowyer, PhD
12:00 – 12:15Abstract #51: Vaccine-induced immunogenicity and protection in a murine model of invasive pulmonary aspergillosis
Emily Rayens
12:15 – 12:30Abstract #37: Modulation of TREM1 signalling in macrophages infected with Aspergillus fumigatus
Irene González Jiménez, PhD
12:30 – 12:55Individualized genetic-based approach for IA prophylaxis
Pierre-Yves Bochud, MD
12.55 – 14.30
Lunch and Poster Session 1

Airways and Diseases

Moderators: Teresa Zelante, PhD, Martin Hönigl, MD & Sven Krappmann, PhD
14:30 – 14:55Regulation of Th2-immunity
David B. Corry, MD
14:55 – 15:10Abstract #46: Single cell approaches reveal the key dendritic cell subsets that coordinate allergic airway inflammation against the fungal allergen Aspergillus fumigatus
Peter Cook, PhD
15:10 – 15:25Abstract #74: Interdependency of host and pathogen protein persulfidation governs disease severity in experimental and human aspergilloses
Jorge Amich, PhD
15:25 – 15:50The structure and immunogenicity of galactomannan
Nikolay Nifantiev, PhD
15:50 – 16:20
Coffee Break

Aspergillus: Entering the Host and Beyond

Moderators: Elaine Bignell, PhD, Yoshitsugu Miyazaki, MD PhD & Gabriele Sass PhD
16:20 – 16:45Siderophores and fungal pathogenesis
Hubertus Haas, PhD
16:45 – 17:00Abstract #79: Iron overload decreases macrophage lysosomal acidification, impairing the clearance of Aspergillus fumigatus conidia
Mikio Kaji
17:00 – 17:15Abstract #73: ROS-dependent and independent host-induced fungal regulated cell death in defence against invasive aspergillosis
Neta Shlezinger, PhD
17:15 – 17:40Modelling IA – how close are predicted antifungal targets?
Thomas Walsh, MD
17:40 – 18:45
Welcome Reception

Go directly to a day’s programme
Thursday | Friday | Saturday

Friday 28 February 2020 – Day 2

Meet the Professor

08:00 – 08:55Difficult cases in fungal sinusitis
Tarik Mohsena MD FRCPC FACP DTM&H & Arunaloke Chakrabarti, MD
08:00 – 08:55How to make a fast and accurate diagnosis – what can the clinician and lab do?
Dea Garcia-Hermoso, PhD & Stéphane Ranque, MD PhD

Emerging Aspergilli

Moderators: Jesús V. Guinea Ortega, PharmD PhD & Stéphane Ranque, MD PhD
09:00 – 09:25Current epidemiology of invasive fungal infections
Nina Khanna, MD
09:25 – 09:40Abstract #82: Mucoricin is a mucorales ricin-like toxin critical for mucormycosis pathogenesis
Ashraf Ibrahim, PhD
09:40 – 10:05Epidemiological surveillance for Aspergillus – is it of any value?
Sophie Loeffert-Frémiot, PhD
10:05 – 10:20Abstract #92: Virus infection of Aspergillus fumigatus (Af) compromises Af in intermicrobial competition
Ioly Kotta-Loizou
10:20 – 10:45Aspergillus calidoustus – epidemiology and outcome
Frederic Lamoth, MD
10:45 – 11:00New support initiatives in aspergillosis and mucormycosis research
Dona Love, PhD & Sonia Sanchez, MD
11:00 – 11:45
Coffee Break and Poster Viewing

Pfizer Satellite Symposium
Dealing with the Threat of Mucormycosis when there is Differential Diagnostic Doubt

Moderator: Robert Krause, MD DTMP
11:45 – 13:15Introduction and scene setting
Robert Krause, MD DTMP
11:55 - 12:05Interactive case study part one – setting the scene of a difficult diagnosis
Dionysios Neofytos, MD PhD MPH
12:05 - 12:30Risk factors for invasive aspergillosis and mucormycosis, and how to pick apart a diagnosis, supported by case studies
Carolina Garcia-Vidal, MD PhD
12:30 - 12:55Treating invasive mould disease in the case of confounding factors
Malgorzata Mikulska, MD PhD
12:55 - 13:05Interactive case study part two – treatment approaches to a complex patient with a complicated infection
Dionysios Neofytos, MD PhD MPH
13:05 - 13:15Discussion, Q&A and close
All
13:15 – 14:00
Lunch (Sponsored by Pfizer)

14:00 – 15:00Poster Viewing

Go directly to a day’s programme
Thursday | Friday | Saturday

Saturday 29 February 2020 – Day 3

Meet the Professor

08:00 – 08:55CLSI/EUCAST: AFST for breakpoints - where we are going?
David R. Andes, MD & Jesús V. Guinea Ortega, PharmD, PhD
07:45 – 08:55Regulatory endpoints for invasive and chronic pulmonary aspergillosis – what is needed?
Oliver Cornely, MD, Thomas F. Patterson, MD, Radu Botgros, MD & Sumathi Nambiar, MD

Resistance in Aspergillus

Moderators: Nina Khanna, MD, Thomas Walsh, MD & Don Sheppard, MD
09:00 – 09:25Acquiring azole resistant Aspergilli – where from?
Dolores Pinheiro, MD
09:25 – 09:40Abstract #59: The negative cofactor 2 complex is a master regulator of drug resistance in Aspergillus fumigatus
Takanori Furukawa, PhD
09:40 – 09:55Abstract #114: The incidence of pulmonary aspergillosis in patients with cystic fibrosis in Russian Federation
Yana Kozlova, MD
09:55 – 10:10Abstract #64: CRISPR-Cas9 mutation and characterization of the most overexpressed transcription factor of swollen state of Aspergillus fumigatus
Uxue Perez-Cuesta
10:10 – 10:35Management of aspergillosis due to azole-resistant Aspergillus fumigatus
Bart-Jan Kullberg, MD PhD
10:35 – 11:05
Coffee Break

Molecular Mechanisms

Moderators: Gordon D. Brown, PhD, Hubertus Haas, PhD & Praveen Juvvadi, PhD
11:05 – 11:30Recognition of DHN-melanin by C–type lectin receptor
Gordon D. Brown, PhD
11:30 – 11:45Abstract #93: Aspergillus fumigatus KnrA is an intrinsically disordered protein and functions as a potential substrate of calcineurin and protein kinase A in the cell wall integrity pathway
Praveen Juvvadi, PhD
11:45 – 12:00Abstract #41: Epithelial uptake of Aspergillus fumigatus spores drives efficient fungal clearance in vivo and is aberrant in chronic obstructive pulmonary disease (COPD) patients
Margherita Bertuzzi, PhD
12:00 – 12:15Abstract #80: Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity
Samuel Gonçalves
12:15 – 12:40Antimicrobial peptides secreted by Aspergillus fumigatus
Sven Krappmann, PhD
12:40 – 14:20
Lunch and Poster Session 2

Mucormycosis Update

Moderators: Oliver Cornely, MD, Frederic Lamoth, MD & Dea Garcia-Hermoso, PhD
14:20 – 14:45One world - one guideline: mucormycosis
Oliver Cornely, MD
14:45 – 15:10Distinguishing invasive mucormycosis from aspergillosis non-invasively
Vladimir Havlicek, PhD
15:10 – 15:25Abstract #89: Ubiquity, diversity, and functional genomics of Mucoromycota and their Betaproteobacterial endosymbionts
Jessie Uehling, PhD
15:25 – 15:40Abstract #55: Why are mucormycetes resistant against voriconazole?
Michaela Lackner, PhD
15:40 – 16:05Mucor species & macrophages
Victoriano Garre, PhD
16:05 – 16:35
Coffee Break

Risks for Aspergillus-Related Diseases: Clinical Hot Spots

Moderators: Chris Kosmidis, MD PhD & Sophie Loeffert-Frémiot, PhD
16:35 – 17:00Challenge for chronic pulmonary aspergillosis – a common but formidable disease
Yoshitsugu Miyazaki, MD PhD
17:00 – 17:15Abstract #117: Prospective evaluation of quality of life and Aspergillus IgG in tuberculosis (TB) patients in Lagos, Nigeria
Rita Oladele, PhD
17:15 – 17:40Biofilm formation by Aspergillus fumigatus – implications for treatment
Don Sheppard, MD
17:40 – 17:55Abstract #34: Altered A. fumigatus cell wall integrity by PC945, a novel inhaled azole
Darius Armstrong-James, MD PhD
17:55 – 18:20The new world of inhaled antifungals & biologics – where might it take us?
Richard B. Moss, MD
18:20 – 18:25
Closing
William J. Steinbach, MD & David A. Stevens, MD
18:30
Snacks and Discussion about AAA 2022